Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR 30 /GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
1. A method of treating or reducing the likelihood of a disease state or condition in a patient or subject in which excessive production or formation of Nox (NADPH oxidase) isoforms leads to excessive ROS production or formation that mediates said disease state or condition comprising administering to said patient or subject in need a compound which inhibits and/or reduces the production and/or formation of said Nox (NADPH oxidase) isoforms in said patient or subject, wherein said disease state or condition is a renal disease state or condition and said compound is according to the chemical structure:
where R is H or an isopropyl group, or a pharmaceutically acceptable salt or mixture thereof.
2. The method according to claim 1 wherein R is H.
3. The method according to claim 1 wherein R is an isopropyl group.
4. The method according to claim 1 wherein said renal disease state or condition is nephropathy, glomerulonephritis, interstitial nephritis, lupus nephritis, chronic kidney disease, idiopathic nephrotic syndrome (INS), obstructive uropathy, polycystic kidney disease or kidney graft rejection.
5. The method according to claim 1 wherein said renal disease state or condition is renal injury, chemical or physical insult resulting in apoptosis or necrosis of renal tissue, chronic kidney disease, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, and/or renal dysplasia, glomerular hypertrophy, tubular hypertrophy, chronic glomerulosclerosis, renal cell carcinoma, chronic tubulointerstitial sclerosis, renal fibrosis, progressive loss of renal function, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, renal dysplasia or glomerular hypertrophy.
6. The method according to claim 1 wherein said renal disease state or condition is proteinuric renal disease, chronic kidney disease or a progressive loss of renal function associated with progressive loss of functioning nephron units.
7. The method according to claim 1 wherein said renal disease state or condition is proteinuric renal disease, chronic kidney disease, renal injury, chronic renal failure, renal replacement therapy, progressive loss of renal function, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, renal dysplasia, glomerular hypertrophy, tubular hypertrophy, chronic glomerulosclerosis, renal cell carcinoma, chronic tubulointerstitial sclerosis or renal fibrosis.
8. The method according to claim 1 wherein said renal disease or condition is chronic kidney disease, diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and/or platinum compounds or kidney disease caused by a hyperactive bladder.
9. The method according to claim 1 wherein said renal disease or condition is chronic kidney disease, a single kidney in a patient or subject or a kidney transplant in a patient or subject.
10. The method according to claim 1 wherein said renal disease state or condition is chronic kidney disease, renal fibrosis, proteinuric renal disease, chronic tubolointerstitial sclerosis or focal segmental glomerulosclerosis (FSGS).
11. The method according to claim 1 wherein said renal disease state or condition is chronic kidney disease, nephropathy, glomerulonephritis, interstitial nephritis, lupus nephritis, idiopathic nephrotic syndrome (INS), focal segmental glomerulosclerosis (FSGS), obstructive uropathy or polycystic kidney disease.
12. The method according to claim 1 wherein said renal disease or condition is chronic kidney disease, membranous nephropathy (MN), diabetic nephropathy, hypertensive nephropathy, membranous glomerulonephritis, membranoproliferative glomerulonephritis (MPGN), rapidly progressive glomerulonephritis (RPGN)), minimal change nephrotic syndrome (MCNS), Autosomal Dominant Polycystic Kidney Disease (ADPKD) or Autosomal Recessive Polycystic Kidney Disease (ARPKD).
13. The method according to claim 1 wherein said renal disease or condition is chronic kidney disease, renal injury, chemical or physical insult resulting in apoptosis, necrosis or loss of functional renal tissue, chronic renal failure, renal replacement therapy, progressive loss of renal function, end-stage renal disease, chronic diabetic nephropathy, hypertensive nephrosclerosis, chronic glomerulonephritis, hereditary nephritis, renal dysplasia, glomerular hypertrophy, tubular hypertrophy, chronic glomerulosclerosis, renal cell carcinoma, chronic tubulointerstitial sclerosis or renal fibrosis.
14. The method according to claim 1 wherein said renal disease or condition is chronic kidney disease, chronic hemodialysis, continuous peritoneal dialysis, kidney transplantation or progressive loss of renal function associated with progressive loss of functioning nephron units.
15. The method according to claim 2 wherein said renal disease state or condition is chronic kidney disease or kidney graft rejection.
16. The method according to claim 5 wherein said renal disease state or condition is chronic kidney disease or end-stage renal disease.
17. The method according to claim 7 wherein said renal disease state or condition is chronic kidney disease or is a single functioning kidney in a patient or subject.